A comparison of the behavior of 64Cu-acetate and 64Cu-ATSM in vitro and in vivo

Journal of Nuclear Medicine

Volumn 55, Issue 1, 2014, Pages 128-134

  Hueting, Rebekka ^a   Kersemans, Veerle ^b   Cornelissen, Bart ^b   Tredwell, Matthew ^a   Hussien, Kamila ^b   Christlieb, Martin ^b   Gee, Antony D ^c   Passchier, Jan ^d   Smart, Sean C ^b   Dilworth, Jonathan R ^a   Gouverneur, Véronique ^a   Muschel, Ruth J ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Copper metabolism; Hypoxia

Indexed keywords

ACETATE CU 64; ACETIC ACID DERIVATIVE; COPPER 64; DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONATE) CU 64; UNCLASSIFIED DRUG; COPPER; COPPER (II) DIACETYL DI(N(4) METHYLTHIOSEMICARBAZONE); COPPER (II) DIACETYL-DI(N(4)-METHYLTHIOSEMICARBAZONE); ORGANOMETALLIC COMPOUND; OXYGEN; THIOSEMICARBAZONE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRAIN CANT; CELL STRAIN EMT6; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; COPPER METABOLISM; DISSOCIATION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG RETENTION; DRUG TUMOR LEVEL; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; OXYGEN BREATHING; PET SCANNER; PRIORITY JOURNAL; RADIOACTIVITY; TISSUE OXYGENATION; 64CU-ACETATE; 64CU-ATSM; ANIMAL; ANOXIA; CANCER TRANSPLANTATION; CBA MOUSE; CELL LINE; CHEMISTRY; COMPARATIVE STUDY; FEMALE; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; TIME; TUMOR CELL LINE;

64CU-ACETATE; 64CU-ATSM; COPPER METABOLISM; HYPOXIA;

ACETATES; ANIMALS; ANOXIA; CELL LINE; CELL LINE, TUMOR; COPPER; COPPER RADIOISOTOPES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED CBA; NEOPLASM TRANSPLANTATION; ORGANOMETALLIC COMPOUNDS; OXYGEN; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; THIOSEMICARBAZONES; TIME FACTORS;

EID: 84894695745     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.119917     Document Type: Article

References (39)

1. Carlin S, Humm JL. PET of hypoxia: current and future perspectives. J Nucl Med. 2012;53: 1171-1174.
2. Fujibayashi Y, Taniuchi H, Yonekura Y, et al. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38: 1155-1160.
3. Vavere AL, Lewis JS. Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia. Dalton Trans. 2007;4893-4902.
4. 64Cu]diacetyl-bis(N 4-methyl-Thiosemicarbazone): a radiotracer for tumor hypoxia. Nucl Med Biol. 2008;35: 393-400.
5. Obata A, Yoshimi E, Waki A, et al. Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent Cu-diacetyl-bis(N4- methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann Nucl Med. 2001;15: 499-504.
6. Maurer RI, Blower PJ, Dilworth JR, et al. Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals. J Med Chem. 2002;45: 1420-1431.
7. Holland JP, Green JC, Dilworth Jr. Probing the mechanism of hypoxia selectivity of copper bis(thiosemicarbazonato) complexes: DFT calculation of redox potentials and absolute acidities in solution. Dalton Trans. 2006;783-794.
8. Holland JP, Barnard PJ, Collison D, et al. Spectroelectrochemical and computational studies on the mechanism of hypoxia selectivity of copper radiopharmaceuticals. Chem Eur J. 2008;14: 5890-5907.
9. Holland JP, Giansiracusa JH, Bell SG, et al. In vitro kinetic studies on the mechanism of oxygen-dependent cellular uptake of copper radiopharmaceuticals. Phys Med Biol. 2009;54: 2103-2119.
10. 64Cu(II)-diacetyl- bis(N4-methylthiosemicarbazone). J Nucl Med. 2006;47: 989-998.
11. Burgman P, O'Donoghue JA, Lewis JS, et al. Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. Nucl Med Biol. 2005;32: 623-630.
12. 64Cu(II)- diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, P2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys. 2005; 61: 1493-1502.
13. 18F]fluoromisonidazole positron emission tomography. Int J Oncol. 2007;30: 873-881.
14. 64Cu-ATSM in a rodent model of cancer. Nucl Med Biol. 2008;35: 713-720.
15. V-Avere AL, Lewis JS. Examining the relationship between Cu-ATSM hypoxia selectivity and fatty acid synthase expression in human prostate cancer cell lines. Nucl Med Biol. 2008;35: 273-279.
16. 64Cu-PTSM in human and murine tumors is influenced by mdr1 protein expression. J Nucl Med. 2009;50: 1332-1339.
17. Dearling JLJ, Packard AB. Some thoughts on the mechanism of cellular trapping of Cu(II)-ATSM. Nucl Med Biol. 2010;37: 237-243.
18. Peng F, Liu J, Wu JS, Lu X, Muzik O. Mouse extrahepatic hepatoma detected on MicroPET using copper (II)-64 chloride uptake mediated by endogenous mouse copper transporter 1. Mol Imaging Biol. 2005;7: 325-329.
19. 64CuCl2. J Nucl Med. 2006;47: 1649-1652.
20. Zhang H, Cai H, Lu X, et al. Positron emission tomography of human hepatocellular carcinoma xenografts in mice using copper (II)-64 chloride as a tracer. Acad Radiol. 2011;18: 1561-1568.
21. 64Cu: implications for molecular imaging of tumor characteristics with copper-based PET tracers. Nucl Med Biol. 2013;40: 345-350.
22. 64Cu labelling of functionalized bis(thiosemicarbazonato) complexes. Chem Commun (Camb). 2010;46: 4052-4054.
23. 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med. 1999;40: 177-183.
24. 64Cu-complexes for the positron emission tomography imaging of hypoxia. J Med Chem. 2008;51: 2985-2991.
25. Mathias CJ, Bergmann SR, Green MA. Development and validation of a solvent extraction technique for determination of Cu-PTSM in blood. Nucl Med Biol. 1993;20: 343-349.
26. Lewis JS, Herrero P, Sharp Terry L, et al. Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetyl-bis(N(4)- methylthiosemicarbazone). J Nucl Med. 2002;43: 1557-1569.
27. 64Cu-labeled bis (selenosemicarbazone) and bis(thiosemicarbazone) complexes as hypoxia imaging agents. Nucl Med Biol. 2005;32: 147-156.
28. Koch CJ. EF5 Procedure Manual. http://www.hypoxia-imaging.org/v2/methods/ ef5manual.htm. Accessed November 7, 2013.
29. Lee J, Siemann DW, Koch CJ, Lord EM. Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts. Int J Cancer. 1996;67: 372-378.
30. Bolte S, Cordelieres FP. A guided tour into subcellular colocalization analysis in light microscopy. J Microsc. 2006;224: 213-232.
31. 64Cu(II): potential combination agents for the PET imaging of hypoxia. J Inorg Biochem. 2010;104: 126-135.
32. Dearling JLJ, Lewis JS, Mullen GED, et al. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-Activity relationships. J Biol Inorg Chem. 2002;7: 249-259.
33. Franko AJ. Hypoxic fraction and binding of misonidazole in EMT6/Ed multicellular tumor spheroids. Radiat Res. 1985;103: 89-97.
34. 18F]-FMISO tumor hypoxia accumulation. PLoS ONE. 2011;6: e25911.
35. Holland JP, Lewis JS, Dehdashti F. Assessing tumor hypoxia by positron emission tomography with Cu-ATSM. Q J Nucl Med Mol Imaging. 2009;53: 193-200.
36. Chia K, Fleming IN, Blower PJ. Hypoxia imaging with PET: which tracers and why? Nucl Med Commun. 2012;33: 217-222.
37. Lewis JS, Sharp TL, Laforest R, et al. Tumor uptake of copper-diacetyl-bis(n4-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med. 2001;42: 655-661.
38. Gray LW, Kidane TZ, Nguyen A, et al. Copper proteins and ferroxidases in human plasma and that of wild-Type and ceruloplasmin knockout mice. Biochem J. 2009;419: 237-245.
39. Cabrera A, Alonzo E, Sauble E, et al. Copper binding components of blood plasma and organs, and their responses to influx of large doses of 65Cu, in the mouse. Biometals. 2008;21: 525-543.